Similar articles

• An autopsy case of intracranial hemorrhage during tissue plasminogen activator infusion.

  Masuoka H, Kotani H, Yazu T, Mizuno O, Miyahara M, Sekoguchi K, Tanaka R, Ueda K, Fukui A, Futagami Y, et al. Masuoka H, et al. Heart Vessels. 1993;8(3):163-5. doi: 10.1007/BF01744802. Heart Vessels. 1993. PMID: 8407727
• The TPA controversy and the drug approval process. The view of the Cardiovascular and Renal Drugs Advisory Committee.

  Kowey PR, Fisher L, Giardina EG, Leier CV, Lowenthal DT, Messerli FH, Pratt CM. Kowey PR, et al. JAMA. 1988 Oct 21;260(15):2250-2. JAMA. 1988. PMID: 3139900 Review. No abstract available.
• Genentech experience with rt-PA (activase).

  Grossbard EB. Grossbard EB. J Am Coll Cardiol. 1987 Feb;9(2):467. doi: 10.1016/s0735-1097(87)80408-4. J Am Coll Cardiol. 1987. PMID: 3100603 No abstract available.
• Risk for intracranial hemorrhage after tissue plasminogen activator treatment for acute myocardial infarction. Participants in the National Registry of Myocardial Infarction 2.

  Gurwitz JH, Gore JM, Goldberg RJ, Barron HV, Breen T, Rundle AC, Sloan MA, French W, Rogers WJ. Gurwitz JH, et al. Ann Intern Med. 1998 Oct 15;129(8):597-604. doi: 10.7326/0003-4819-129-8-199810150-00002. Ann Intern Med. 1998. PMID: 9786806
• Tissue plasminogen activator.

  Loscalzo J, Braunwald E. Loscalzo J, et al. N Engl J Med. 1988 Oct 6;319(14):925-31. doi: 10.1056/NEJM198810063191407. N Engl J Med. 1988. PMID: 3138537 Review. No abstract available.